News

Avella selected by Takeda Pharmaceuticals to distribute NINLARO® (ixazomib)

December 3, 2015| CATEGORIES: Oncology , Press Release

New FDA-approved drug is the first oral therapy of its kind designed to treat multiple myeloma

 

Avella Specialty Pharmacy announced today that it has been selected by Takeda Pharmaceutical Company Limited to distribute NINLARO® (ixazomib), a  medication for individuals diagnosed with multiple myeloma. NINLARO is the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. avella-SP-logo-color_reverse-stack-thumb_f681f166-b7b3-4cd1-8690-1ea81e747449-prv (1).jpg“NINLARO offers patients a new approach—an all-oral triplet regimen—to treating multiple myeloma with a proteasome inhibitor. Avella’s pharmacists will be working closely with patients to ensure that medication adherence and patient safety are maintained throughout the entire treatment,” said Leslie Yendro, RN, Vice President of Business Development for Avella Specialty Pharmacy. “Our commitment to providing expert guidance and ongoing support to patients is one of the reasons why manufacturers continue to turn to Avella in order to distribute breakthrough specialty drugs.”

Multiple myeloma is a blood cancer that forms in plasma cells. Plasma cells are found in bone marrow and play a critical role in helping the immune system fight infections. When these cells become cancerous, they can produce tumors called plasmacytomas. Patients with multiple myeloma have more than one of these tumors. NINLARO is a proteasome inhibitor that works by blocking certain enzymes produced by cancerous cells, which in turn prevents these cells from surviving and growing.

About Avella Specialty Pharmacy

Headquartered in Phoenix, Arizona, Avella Specialty Pharmacy is a National Accredited Specialty Pharmacy, providing individualized care and support to patients since 1996. Avella's clinical pharmacists and staff members are experts in managing complex disease states and providing compassionate care. The company offers a nationwide distribution service to complement its retail locations. Avella reached 2,605th on Inc. Magazine's 2015 list of the 5,000 fastest-growing private companies in the country. In addition, the Arizona Corporate Excellence Awards has named Avella Specialty Pharmacy as the second fastest-growing private company based in the state. For more information, please visit www.avella.com.


News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe
Featured Video
Photo of Brian Halligan
Path of a Specialty Prescription
The path of a specialty prescription is complex. This video details each step of the path and the unique offerings of Avella.
News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe